Vassiliou, A.; Osunronbi, T.; Enyioma, S.; Rago, G.; Karathanasi, A.; Ghose, A.; Sheriff, M.; Mikropoulos, C.; Sanchez, E.; Moschetta, M.; Chargari, C.; Rassy, E.; Boussios, S. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study. Cancers2023, 15, 4432.
Vassiliou, A.; Osunronbi, T.; Enyioma, S.; Rago, G.; Karathanasi, A.; Ghose, A.; Sheriff, M.; Mikropoulos, C.; Sanchez, E.; Moschetta, M.; Chargari, C.; Rassy, E.; Boussios, S. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study. Cancers 2023, 15, 4432.
Vassiliou, A.; Osunronbi, T.; Enyioma, S.; Rago, G.; Karathanasi, A.; Ghose, A.; Sheriff, M.; Mikropoulos, C.; Sanchez, E.; Moschetta, M.; Chargari, C.; Rassy, E.; Boussios, S. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study. Cancers2023, 15, 4432.
Vassiliou, A.; Osunronbi, T.; Enyioma, S.; Rago, G.; Karathanasi, A.; Ghose, A.; Sheriff, M.; Mikropoulos, C.; Sanchez, E.; Moschetta, M.; Chargari, C.; Rassy, E.; Boussios, S. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study. Cancers 2023, 15, 4432.
Abstract
Purpose: Metastatic spinal cord compression (MSCC) is a severe complication of cancer that can lead to irreversible neurological impairment, necessitating prompt recognition and intervention. This retrospective, single-center study aimed to determine the prognostic factors and survival rates among patients presenting with MSCC secondary to lung cancer. Methods and Materials: We identified 74 patients with epidural metastases-related spinal cord compression and a history of lung cancer, through the electronic database of Medway Maritime Hospital in United Kingdom (UK), spanning the period from April 2016 to September 2021. Among them, 39 were below 55 years old, while 35 were aged 55 years or older, whereas 24 patients were diagnosed with small cell lung cancer (SCLC), and 50 patients had non-small cell lung cancer (NSCLC). Results: The median overall survival (OS) was 5.5 months, with 52 out of 74 patients dying within 6 months of the diagnosis of MSCC. For the entire cohort, the statistically significant variables on multi-variate analysis were: cancer type (NSCLC had improved OS), number of involved vertebrae (one to two vertebrae involvement had improved OS) and time taken to develop motor deficits (≤10 days to develop motor deficits had worsened OS). For the NSCLC cohort, the statistically significant variables on multivariate analysis were: molecular alterations (patients with epidermal growth factor receptor (EGFR) mutation), pre-treatment ambulatory status, Eastern Cooperative Oncology Group (ECOG) performance status, and time taken to develop motor deficits. Conclusions: Within the entire cohort, patients diagnosed with NSCLC and spinal metastases affecting one to two vertebrae exhibited enhanced OS. Within the NSCLC subgroup, those with EGFR mutations, who were ambulatory, and possessed an ECOG performance status of 1-2, demonstrated improved OS. In both the entire cohort and NSCLC subgroup, the development of motor deficits within a period of ≤10 days was associated with poorer OS.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
